Expression of cd 95 (fas/apo-1) in non-hodgkin's lymphoma | ||
| The Egyptian Journal of Surgery | ||
| Volume 21, Issue 3, July 2002, Pages 983-989 PDF (3.5 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejsur.2002.403209 | ||
| Authors | ||
| Solafa EL-Sharawy* 1; Tarek Badrawy2; Sherif Koth2 | ||
| 1Departments of Clinical Pathology (Hematology Unit), Mansoura Faculty of Medicine, Mansoura University Hospital | ||
| 2Department of General Surgery, Mansoura Faculty of Medicine, Mansoura University Hospital | ||
| Abstract | ||
| Apoptosis mediated by the CD95 (FAS/ APO-1) molecule plays a crucial role in the regulation of B-cell immune response. In this study, the expression of CD95 was examined by flow cytometry & immunohistochemistry in 52 cases of newly diagnosed non Hodgkin's lymphomas (NHLs) and in 12 cases of reactive hyperplastic lymph node (RHL). Also, serum soluble FAS Ligand level ( s FAS L) was assessed in these patients as well as in 10 healthy control with matched age and sex. Compared to diffuse large cell lymphoma and Burkitt's lymphoma, low grade lymphoma more frequently expressed CD95. However, CD95 expression did not correlate with ESR , LDH and /32 microglobulin. In this study, sFASL was significantly different in different histopathological subtypes and stages of NIILs and the highest level was in high grade lymphoma and stage IV . It was significantly correlated with ESR , LDH and )32 microglobulin . So, the infrequent expression of CD95 in high grade lymphoma suggests an association between loss of CD95 expression/ function and more aggressive tumour grade. So s FAS L may be putative independent prognostic factor and may be an impediment to the development of FAS-based therapies for NHLs. | ||
| Keywords | ||
| Non Hodgkin's lynzphoma; CD95 | ||
|
Statistics Article View: 21 PDF Download: 14 |
||
